LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.03 -5.5

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.02

Max

1.09

Põhinäitajad
By Trading Economics
Sissetulek	15M -38M
Müük	-231K 1.6M
Aktsiakasum	-0.32
Kasumimarginaal	-2,309.454
Töötajad	181
EBITDA	4.3M -38M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+342.73% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	11. aug 2025

Turustatistika
By TradingEconomics
Turukapital	14M 136M
Eelmine avamishind	6.53
Eelmine sulgemishind	1.03

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

27. juuni 2025, 20:51 UTC

Tulu

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27. juuni 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27. juuni 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27. juuni 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27. juuni 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27. juuni 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:57 UTC

Omandamised, ülevõtmised, äriostud

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27. juuni 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27. juuni 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27. juuni 2025, 18:39 UTC

Market Talk

Tulu

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27. juuni 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27. juuni 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27. juuni 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27. juuni 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27. juuni 2025, 17:08 UTC

Tulu

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27. juuni 2025, 16:52 UTC

Omandamised, ülevõtmised, äriostud

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27. juuni 2025, 16:22 UTC

Tulu

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27. juuni 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27. juuni 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27. juuni 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27. juuni 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27. juuni 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

342.73% tõus

12 kuu keskmine prognoos

Keskmine 4.87 USD 342.73%

Kõrge 12 USD

Madal 2 USD

Põhineb 9 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

9 ratings

Osta

Hoia

Müü

Põhineb 9 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.